Arcturus Therapeutics Holdings (ARCT) Share-based Compensation (2018 - 2026)

Arcturus Therapeutics Holdings' Share-based Compensation history runs 9 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• Quarterly Share-based Compensation fell 35.08% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.1 million (up 3443.62% YoY) and the FY2025 annual result came in at $30.1 million, down 37.94% from the prior year.
• Share-based Compensation was $4.3 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $6.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $10.1 million in Q1 2024 and bottomed at -$26.3 million in Q4 2024.
• A 5-year average of $5.7 million and a median of $7.4 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation slumped 398.0% — and 2025, when it surged 125.95%.
• Arcturus Therapeutics Holdings' Share-based Compensation stood at $6.5 million in 2022, then surged by 34.99% to $8.8 million in 2023, then slumped by 398.0% to -$26.3 million in 2024, then jumped by 125.95% to $6.8 million in 2025, then tumbled by 36.56% to $4.3 million in 2026.
• Business Quant data shows ARCT's Share-based Compensation at $4.3 million in Q1 2026, $6.8 million in Q4 2025, and $5.7 million in Q3 2025.